Evolution of Staphylococcus aureus under vancomycin selective pressure: the role of the small-colony variant phenotype

Antimicrob Agents Chemother. 2015 Feb;59(2):1347-51. doi: 10.1128/AAC.04508-14. Epub 2014 Dec 1.

Abstract

Staphylococcus aureus small-colony variants (SCVs) often persist despite antibiotic therapy. Against a 10(8)-CFU/ml methicillin-resistant S. aureus (MRSA) (strain COL) population of which 0%, 1%, 10%, 50%, or 100% was an isogenic hemB knockout (Ia48) subpopulation displaying the SCV phenotype, vancomycin achieved maximal reductions of 4.99, 5.39, 4.50, 3.28, and 1.66 log10 CFU/ml over 48 h. Vancomycin at ≥16 mg/liter shifted a population from 50% SCV cells at 0 h to 100% SCV cells at 48 h, which was well characterized by a Hill-type model (R2>0.90).

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Methicillin-Resistant Staphylococcus aureus / drug effects
  • Microbial Sensitivity Tests
  • Staphylococcus aureus / drug effects*
  • Vancomycin / pharmacology*

Substances

  • Anti-Bacterial Agents
  • Vancomycin